Top Injectable Manufacturer in Panama – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 1 hour ago
- 10 min read
Last Updated: August 27, 2026
TL;DR: Panama rewrote its medicines law in 2024 and a lot of the advice in circulation is now out of date. Ley 419 de 2024 replaced Ley 1 de 2001 and, unusually, regulates medicines and the public procurement of medicines in a single statute; Decreto Ejecutivo No. 27 de 10 de mayo de 2024 implements it. Registration sits with the Direccion Nacional de Farmacia y Drogas, is filed as a fully digital file, must be lodged by a Panamanian lawyer with a licensed pharmacist's endorsement and that of the national pharmacists' college, and runs either as a full procedure with prior laboratory testing or as an abbreviated one without it. A separate 2025 decree, as amended, adds automatic recognition for products registered by a WHO-Listed Authority – a route an Indian-registered product cannot use, which we say plainly. Farbe Firma Pvt Ltd fills sterile injectables on ISO Class 5 aseptic lines in a WHO-GMP certified facility in Gujarat, India, and builds the zone IVb stability and legalisation package a Panamanian distributor needs.
Key Takeaways
The law changed in 2024, and guidance written against Ley 1 de 2001 is stale. Ley 419 de 1 de febrero de 2024 subrogated the 2001 statute and merged medicines regulation with the public procurement of medicines into one instrument; Decreto Ejecutivo No. 27 de 10 de mayo de 2024, published in Gaceta Oficial 30028-C, is the operative regulation and runs to well over a hundred articles. Anything that describes Panamanian registration by reference to the 2001 law, or to the 2019 implementing decree, or to the Ministry's 2022 user guide with its paper dossier and folio numbering, is describing a regime that has been replaced by a digital one.
Panama accepts authenticated copies and electronic apostilles for GMP evidence – the opposite of what is widely repeated. It is often said that Panama refuses certified copies and digital GMP certificates and insists on a physical legalised original. The current decree says otherwise. Article 28 allows the free-sale certificate in original or authenticated copy of the legalised document, or a WHO-type certificate of pharmaceutical product, and expressly includes the electronic apostille; Article 29 allows the GMP certificate in original or authenticated copy, and provides that where a regulator does not issue GMP certificates but maintains an electronic tool holding the complete manufacturer and GMP information, notarial copies of those official documents are accepted. Both certificates are treated as valid for two years unless the issuing authority says otherwise.
The WHO-Listed Authority fast lane exists, and an Indian-registered product cannot use it. Decreto Ejecutivo No. 2 de 7 de enero de 2025, as amended, grants automatic recognition to human medicines manufactured and registered in countries whose regulator appears on the WHO-Listed Authority list, with no prior laboratory analysis, a response due within ten working days and a single round of observations answerable in five. India's CDSCO is not a WHO-Listed Authority, so a product resting on an Indian registration must use the ordinary procedure – with prior analytical testing – or the abbreviated procedure if the same product is registered and marketed under a high-standard authority. A supplier who implies otherwise is selling you a timeline that does not exist.
Selling to the public system means selling through a Panamanian company. Ley 419 obliges the Ministry of Health and the Caja de Seguro Social to run joint purchases, held on the PanamaCompra portal, and the Ministry's national medicines director stated in March 2026 that the companies able to take part are those constituted in the country and authorised by the Direccion Nacional de Farmacia y Drogas. Every pharmaceutical establishment needs a two-year operating licence in its own category – droguería, agencia distribuidora, manufacturing or conditioning laboratory – and a permanently Panama-resident representative is required for registration. The manufacturer's job is to make that partner unbeatable on file quality; it is not to bid.
Introduction: Why Panama Demands a Premium Injectable Manufacturer in Panama
Panama runs two public health systems side by side, and that structure explains almost everything about how medicines are bought there. The Caja de Seguro Social protected 2,806,769 people in 2024, 62.2 per cent of the population on the national statistics institute's figures, and operates its own network of facilities; the Ministry of Health provides for those the Caja does not cover, through a separate network. Two buyers, two sets of facilities, two purchasing habits – which is precisely why Ley 419 de 2024 made joint purchasing a legal obligation rather than a good intention, and why the March 2026 joint exercise was framed around some 375 line items covering chronic-disease medicines, antibiotics and cancer treatments, with the Caja, the Ministry and the boards of the Hospital del Niño, the Hospital Santo Tomás and the Hospital José Domingo de Obaldía all buying together.
The demand side has a clear injectable centre of gravity and a documented supply problem. The Caja's haemodialysis population rose from 2,277 patients in December 2024 to 2,438 by April 2026, better than seven per cent growth in sixteen months, with roughly four in five renal replacement patients on haemodialysis – a caseload that consumes heparin, iron, erythropoiesis-stimulating agents, antibiotics and infusion fluids continuously. Against that, the Caja publicly acknowledged shortages and activated emergency purchasing, an internal audit found expired stock across several storage points with investigations covering medicines and supplies worth more than US$2.5 million, and in September 2025 a commission for the evaluation of critical shortage was created by executive decree, bringing in the ombudsman, the medical association, the pharmacists' college and patient federations alongside the two buyers. Panama is not short of money for medicines. It is short of reliable delivery.
What Sets a World-Class Injectable Manufacturer in Panama Apart
The first differentiator is knowing which of the three registration routes applies to you and not overpromising the fast one. Decreto Ejecutivo No. 27 provides an ordinary procedure with full technical and analytical evaluation, in which prior laboratory testing at the Instituto Especializado de Análisis is required and paid for separately, and an abbreviated procedure for medicines already registered and marketed in countries whose regulators are recognised as high-standard, in which Article 21 dispenses with prior analytical testing. On top of those sits the 2025 automatic-recognition decree for WHO-Listed Authority registrations. The honest position for an Indian manufacturer is that the third route is closed on an Indian registration alone, the second depends on whether the same product carries a high-standard-authority registration, and the first is the one to plan and resource for.
The second is treating the filing chain as part of the technical package. An application must be lodged through the digital platform by a Panamanian lawyer, carry the endorsement of a licensed pharmacist as technical responsible and the endorsement of the Colegio Nacional de Farmacéuticos, and be supported by a notarised power of attorney from the holder or manufacturer; dossier documents must be in Spanish, with foreign-language material translated by an authorised public interpreter, though clinical studies may be filed in English with a Spanish benefit-risk summary and certificates of analysis in either language. Deficiencies carry a three-month window, and missing it does not pause the file – it returns it, and the applicant starts a wholly new application and loses the original case numbers. A manufacturer who supplies clean, correctly legalised, correctly translated documents the first time is protecting the distributor from a restart.
Quality Systems Behind Every Injectable Supplied to Panama
Farbe Firma fills sterile injectables on ISO Class 5 aseptic lines inside a WHO-GMP certified facility in Gujarat, India, with environmental monitoring, media fills, operator qualification, filter integrity and container-closure integrity testing run as a continuous programme. Release testing is performed against IP, USP, BP and EP monographs using HPLC and GC for assay and related substances, Karl Fischer where the presentation requires it, and LAL for bacterial endotoxins, with sterility testing on every sterile lot. Panama makes particular use of this at the border: biological products may not be imported or marketed without the batch certificate of analysis in original or authenticated copy signed by the manufacturer's quality assurance head, vaccines and homologous blood derivatives require lot-by-lot release authorised by the National Director, and heparin sodium products require certificates of analysis for both the active and the finished product together with a proton NMR test on the manufactured active lot.
Stability is the point where Panama is unforgiving, and it is specific. Panama is climatic zone IVb – hot and very humid – and says so expressly in the 2025 recognition decree, with stability studies following the Central American technical regulation on stability that Panama adopted by Decreto Ejecutivo No. 850 de 4 de agosto de 2015. We generate ICH Q1A(R2) long-term and accelerated data with photostability under ICH Q1B in the actual container-closure system that will ship, on zone IVb conditions rather than on temperate data borrowed from a European or North American file. A GMP certificate is required for every establishment involved in manufacture, and separately for the conditioner where packing happens elsewhere, so our site documentation is maintained per-site and legalisation-ready rather than assembled at the point of need.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Panama for Global Buyers
Panama's Central American regulatory layer is real, but it is Panama's own, and this matters because it is easy to assume that a neighbour's rules transfer. Panama gave effect to the current Central American technical regulation on sanitary registration by Resolución No. 126 de 16 de julio de 2021, and adopted the regulations on pharmaceutical labelling, stability studies and analytical method validation by its own executive decrees 849, 850 and 851, all of 4 August 2015. Decreto Ejecutivo No. 27 then hard-wires those instruments into current practice, requiring registration to comply both with the statute and with the Central American technical regulations adopted by the Direccion Nacional de Farmacia y Drogas, and governing renewal by reference to them. Registration validity runs five years on that basis. What we will not tell you is that a Panamanian registration travels to another Central American country, because we have not verified that it does.
There are two structural openings a manufacturer should know about. The first is the second-distributor route: a distributor other than the registered one may import an identical product under a certification of importation under a valid sanitary registration, supported by the manufacturer's attestation of lawful manufacture to approved specifications, a certificate of pharmaceutical product or free-sale certificate with a GMP certificate, original samples, Spanish primary and secondary labelling and an establishment licence – with the first batch subject to prior control and not marketable until analytical results are presented. The second is the Colón Free Zone, where the decree exempts foreign companies with no physical presence in the zone that operate for re-export only under a special represented-company key, working through a representing user company that must itself hold an operating licence from the Direccion Nacional de Farmacia y Drogas. That is the lawful structure for using Panama as a regional hub.
Farbe Firma Pvt Ltd works as both manufacturer and CDMO, which fits a market where the same molecule may need to serve a joint public tender line and a private distributor's own-label presentation simultaneously. We supply dry powder vials, liquid ampoules and vials, lyophilised presentations and small-volume parenterals across anti-infectives, analgesia, anaesthesia, oncology support, nephrology and critical care; we run own-label and technology-transfer programmes; and we prepare CTD and ACTD dossiers, DMF and CEP-referenced active-substance documentation and apostilled certification for more than 30 export markets. For a Panamanian droguería or agencia distribuidora the practical offer is a manufacturer whose zone IVb stability, per-site GMP documentation and Spanish-ready artwork arrive complete, so the three-month deficiency window never becomes a restart.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Who regulates medicines and injectables in Panama, and under what law?
The Dirección Nacional de Farmacia y Drogas of the Ministerio de Salud. It issues, suspends, modifies, renews and cancels the sanitary registration and runs pharmacovigilance, pre-market and post-market control and the inspection of establishments, and it has statutory power to certify Good Manufacturing Practice following audit. The governing statute is Ley 419 de 1 de febrero de 2024, which subrogated Ley 1 de 10 de enero de 2001 and which regulates both medicines and the public procurement of medicines; the implementing regulation is Decreto Ejecutivo No. 27 de 10 de mayo de 2024, published in Gaceta Oficial Digital No. 30028-C. Filing is fully digital through the authority's platform.
Does Panama accept a digital or copied GMP certificate, or must it be a legalised original?
The current decree accepts more than is commonly claimed. The free-sale certificate may be presented in original or in authenticated copy of the legalised document, or replaced by a WHO-type certificate of pharmaceutical product, and the text expressly includes the electronic apostille; no more than two years may separate issue and filing unless the issuing authority states a different validity. The GMP certificate may likewise be presented in original or authenticated copy, and where the regulator does not issue such certificates but maintains an electronic tool containing the complete manufacturer and GMP information, notarial copies of those official documents are accepted. A separate GMP certificate is needed for each establishment involved in manufacture, and for the conditioner if packing occurs in another country. India is a party to the Apostille Convention, so apostille is the practical authentication route from an Indian site.
Can an Indian-manufactured injectable use Panama's automatic recognition route?
Not on an Indian registration. The 2025 decree, as amended, grants automatic recognition only where the medicine is manufactured and registered in a country whose regulator is on the WHO-Listed Authority list, and India's CDSCO is not on that list. The route requires a legalised power of attorney to a person permanently resident in Panama, a certificate of pharmaceutical product in original, legalised or apostilled form with GMP compliance annexed for every manufacturing site, a legalised or apostilled copy of the complete dossier as filed in the country of registration, and zone IVb stability studies; the authority then responds within ten working days with one round of observations. An Indian site should plan for the ordinary procedure, which includes prior analytical testing, unless the same product also carries a high-standard-authority registration that opens the abbreviated route.
How does an Indian manufacturer sell into Panama's public health system?
Through a Panamanian partner, not directly. Joint purchases by the Ministry of Health and the Caja de Seguro Social are held on the PanamaCompra portal, and the Ministry's national director of medicines and supplies stated in March 2026 that participation is open to companies constituted in the country and authorised by the Dirección Nacional de Farmacia y Drogas. That partner must hold an operating licence in the right category – a droguería for import and wholesale of pharmaceutical products, or an agencia distribuidora for import, storage, distribution and transport – renewed every two years. Import itself requires an authorisation, a valid registration or an importation certification under a valid registration, a customs pre-declaration, a compliant invoice and a cargo manifest. For scale reference, the joint call published in October 2024 covered 220 line items at a reference price of about US$124.4 million.
What makes Farbe Firma a suitable injectable manufacturer for Panama?
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling on ISO Class 5 aseptic lines and exporting to more than 30 countries. For Panama specifically we generate ICH Q1A(R2) and Q1B stability on climatic zone IVb conditions rather than adapting temperate data, maintain per-site and per-conditioner GMP documentation in a form that authenticates cleanly by apostille, issue batch certificates of analysis signed by the quality assurance head in the form the import rules require for biological products, and can supply active and finished-product certificates plus proton NMR data where heparin sodium is involved. We work to IP, USP, BP and EP monographs, prepare CTD and ACTD dossiers, and provide Spanish-ready artwork and insert content so the translation and legalisation chain does not become the reason a file is returned. Contact director@farbefirma.org to discuss a specific molecule, tender line or own-label programme.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments